These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38892306)

  • 21.
    Philippsen GS; Seixas FAV
    J Biomol Struct Dyn; 2024 Aug; 42(12):6440-6447. PubMed ID: 37424215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
    Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
    Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel inhibitors of SARS-CoV-2 main protease.
    Zheng L; Chen Y; Bao J; He L; Dong S; Qi Y; Zhang JZH
    J Biomol Struct Dyn; 2022; 40(23):12526-12534. PubMed ID: 34472424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.
    Sur VP; Sen MK; Komrskova K
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational Approach toward COVID-19's Main Protease Inhibitors: A Hierarchical Biochemoinformatics Analysis.
    Bastos RS; de Aguiar CPO; Cruz JN; Ramos RS; Kimani NM; de Souza JSN; Chaves MH; de Freitas HF; Pita SSR; Santos CBRD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are protein-ligand docking programs good enough to predict experimental poses of noncovalent ligands bound to the SARS-CoV-2 main protease?
    Llop-Peiró A; Macip G; Garcia-Vallvé S; Pujadas G
    Drug Discov Today; 2024 Oct; 29(10):104137. PubMed ID: 39151594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ensemble docking based virtual screening of SARS-CoV-2 main protease inhibitors.
    Fomina AD; Uvarova VI; Kozlovskaya LI; Palyulin VA; Osolodkin DI; Ishmukhametov AA
    Mol Inform; 2024 Aug; 43(8):e202300279. PubMed ID: 38973780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel inhibitors of SARS-CoV-2 main protease (M
    Verma S; Patel CN; Chandra M
    J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.
    Guo S; Xie H; Lei Y; Liu B; Zhang L; Xu Y; Zuo Z
    Bioorg Chem; 2021 May; 110():104767. PubMed ID: 33667900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of terpenoids as potential inhibitors of SARS-CoV-2 (main protease) and spike (RBD) via computer-aided drug design.
    Hadni H; Fitri A; Touimi Benjelloun A; Benzakour M; Mcharfi M; Benbrahim M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8145-8158. PubMed ID: 37548619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
    Sardanelli AM; Isgrò C; Palese LL
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.
    Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J
    Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.
    T MK; K R; James N; V S; K R
    Biotechnol Appl Biochem; 2021 Aug; 68(4):712-725. PubMed ID: 33797130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.